Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease
Conditions
Interventions
TL-925
Placebo
Locations
4
United States
Aesthetic Eye Care
Newport Beach, California, United States
Vision Institute
Colorado Springs, Colorado, United States
Michael Washburn Center for Ophthalmic Research, LLC.
Indianapolis, Indiana, United States
Andover Eye Associates
Andover, Massachusetts, United States
Start Date
February 27, 2023
Primary Completion Date
July 11, 2023
Completion Date
July 11, 2023
Last Updated
November 18, 2023
NCT07463950
NCT07363824
NCT07396441
NCT05865457
NCT05865379
NCT06984549
Lead Sponsor
Telios Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions